Ibrutinib (Imbruvica▼): Reported cases of ventricular tachyarrhythmia and risk of hepatitis B reactivation and opportunistic infections

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Ibrutinib an inhibitor of Bruton’s tyrosine kinase (BTK), involved in the maturation of B-cells. Ibrutinib is indicated for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, chronic lymphocytic leukaemia (CLL), including CLL with deletion 17p and Waldenstrӧm’s macroglobulinaemia.

In a 2017 study 17 cases have been identified of which 11 cases of ventricular tachycardia/ventricular fibrillation and 6 cases of sudden cardiac death in patients exposed to ibrutinib. Temporarily discontinue ibrutinib in patients who develop signs or symptoms of ventricular tachyarrhythmia, including, but not limited to, palpitations, chest pain, dyspnoea, dizziness, or fainting. Perform a complete clinical benefit-risk assessment before reinitiating therapy.

8 cases of hepatitis B reactivation were identified in...